Cebeci I, Kantarci A, Firatli E, Carin M, Tuncer O
Department of Periodontology, Faculty of Dentistry, University of Istanbul, Turkey.
J Periodontol. 1996 Nov;67(11):1201-5. doi: 10.1902/jop.1996.67.11.1201.
Cyclosporine A (CsA) and verapamil are two agents used in renal transplantation, both of which are suspected of inducing gingival overgrowth. This study was conducted to investigate the effect of verapamil on the severity and prevalence of CsA-induced gingival overgrowth. Fifty-one (51) renal transplant recipients (total group) of whom 22 were using only CsA (Group A) and 29 of whom were prescribed CsA + verapamil (Group B) were evaluated for various periodontal and pharmacological parameters. No statistically significant differences were found in age, sex, plaque index, gingival index, calculus index, probing depth, CsA oral dose, CsA whole blood level, duration of CsA therapy, azathioprine dose, and prednisolone dose. Although the prevalence of the gingival overgrowth was more pronounced in CsA + verapamil group compared to CsA group (51.72% vs. 40.91%), the difference was not statistically significant. Similarly, the severity of gingival overgrowth, although more manifest in CsA + verapamil group than CsA patients (34.24% vs. 28.91%), was not significantly different. Gingival overgrowth scores in the main group, CsA, and CsA + verapamil groups were found to be positively correlated to periodontal probing depths (r = 0.60, r = 0.70, r = 0.52, respectively) and the gingival index (r = 0.60, r = 0.70, r = 0.54, respectively). CsA oral dose, whole blood level, and duration of CsA therapy were not found to be correlated with the gingival overgrowth in either group. Likewise, the dose of verapamil and the duration of verapamil therapy were not correlated with the gingival overgrowth in Group B. This study indicates that verapamil, when prescribed as the calcium channel blocker in renal transplant patients, has no augmenting effect on the severity and the prevalence of CsA-induced gingival overgrowth.
环孢素A（CsA）和维拉帕米是肾移植中使用的两种药物，二者均被怀疑会导致牙龈增生。本研究旨在调查维拉帕米对CsA诱导的牙龈增生的严重程度和患病率的影响。对51名肾移植受者（总组）进行了评估，其中22名仅使用CsA（A组），29名同时服用CsA +维拉帕米（B组），评估了各种牙周和药理学参数。在年龄、性别、菌斑指数、牙龈指数、牙石指数、探诊深度、CsA口服剂量、CsA全血水平、CsA治疗持续时间、硫唑嘌呤剂量和泼尼松龙剂量方面未发现统计学上的显著差异。尽管与CsA组相比，CsA +维拉帕米组牙龈增生的患病率更高（51.72%对40.91%），但差异无统计学意义。同样，牙龈增生的严重程度，虽然在CsA +维拉帕米组比CsA组患者更明显（34.24%对28.91%），但也没有显著差异。发现主要组、CsA组和CsA +维拉帕米组的牙龈增生评分与牙周探诊深度呈正相关（分别为r = 0.60、r = 0.70、r = 0.52）和牙龈指数呈正相关（分别为r = 0.60、r = 0.70、r = 0.54）。在两组中均未发现CsA口服剂量、全血水平和CsA治疗持续时间与牙龈增生相关。同样，B组中维拉帕米的剂量和维拉帕米治疗的持续时间与牙龈增生也不相关。本研究表明，当作为钙通道阻滞剂给肾移植患者开维拉帕米时，它对CsA诱导的牙龈增生的严重程度和患病率没有增强作用。
